Positive Simulation Data Puts This Biotech in Prime Position Against the Opioid Crisis

Positive data. A breakthrough opioid safeguard. And a biotech suddenly at the center of a $50B crisis.

There’s a reason why Palantir only partners with serious operators.

Their software is used by the U.S. military, intelligence agencies, and Fortune 500s.

So when they announce a strategic collaboration in the autonomous robotics space, it’s worth watching closely.

Their newest partner?

A company with more than 4 million hours of autonomous fieldwork.

Real deployments. Real data. Real revenue.

This means faster incident detection.  Smarter machine learning.

And the kind of predictive security that could transform cities, campuses, and corporations.

This isn’t a beta test.  This is live and expanding.

And while the market sleeps, early investors may have a limited window to act.

Don’t wait for the headlines.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street fell today as rising jobless claims signaled a weakening labor market, while a retail slump led by Walmart and lingering tariff-driven inflation fears weighed on sentiment.

Dayforce Inc. (NYSE: DAY) has entered into a definitive agreement to be acquired by Thoma Bravo in a $12.3 billion all-cash transaction.

The deal values the human resources software provider at $70 per share, giving shareholders a direct cash exit as the company transitions to private ownership under its existing brand.

For equity holders, the buyout offers a guaranteed premium and immediate liquidity, thereby eliminating uncertainty surrounding valuation and ending public participation in Dayforce’s future growth.

Investors who remain in the stock until its closing, expected in early 2026, will be bought out, after which the shares will no longer be traded on the NYSE.

Looking at the broader market, this move signals private equity’s continued appetite for recurring-revenue SaaS platforms.

Dayforce has built a reputation as a leader in workforce management technology, and the premium paid reflects how private buyers value long-term contracts and sticky enterprise demand.

The transaction highlights consolidation momentum in HR tech, where scale and integration capabilities are driving competitive advantage.

The buyout offers current shareholders certainty and a cash value, while underscoring that strategic investors see a deeper upside in Dayforce than the public markets capture.  

For observers of the HR tech sector, the transaction serves as a reminder that growth potential is often recognized first by private capital before public markets fully value it.

Apple (NASDAQ: AAPL) has increased the monthly subscription fee for its ad-free streaming service, Apple TV+, to $12.99 in the U.S. and select global markets.

The new rate is $3 higher than before, while the annual plan and Apple One bundle pricing remain unchanged.

Rising costs for premium content and a competitive streaming market frame this decision, but for equity holders, the bigger story lies in Apple’s ability to exercise pricing power.

Services revenue has become one of the company’s strongest growth drivers, and incremental price hikes expand margins more efficiently than hardware sales alone.

By maintaining bundle pricing, Apple is also signaling a push to drive customers into its broader ecosystem.

The stickiness of Apple One makes churn less likely, even as competing platforms such as Netflix, Disney+, Amazon Prime Video, and Peacock have recently raised their prices.

That industry-wide trend provides cover for Apple’s move, minimizing the risk of subscriber pushback.

Investors studying Apple’s direction should note that TV+ may remain a smaller piece of overall services revenue, yet every step toward higher recurring income supports valuation stability.

The pricing adjustment reinforces Apple’s strategy to steadily deepen recurring revenue streams, offering long-term shareholders confidence in the company’s ability to expand beyond hardware dependence.

ow would it feel to double your money by this time next year?

From thousands of stocks, only 5 have emerged with the best chance to gain +100% or more in the months ahead.

You can see all five of these tickers — absolutely free.

Just download the newly released 5 Stocks Set to Double special report from Zacks.

While we can’t guarantee future performance, previous editions of this report have delivered gains of +175%, +498%, and even +673¹.

The newest picks could be just as profitable.

Act fast — this opportunity ends at MIDNIGHT TONIGHT.

While the market celebrates chipmakers, ASML (NASDAQ: ASML) is trading at a significant discount, creating a compelling opportunity for investors who can look past the emotional noise.

The company is the sole enabler of the most advanced chips, making it an indispensable player in the AI revolution.

Fear, not fundamentals, drives the current valuation gap.

The market is punishing the stock for its exposure to China, despite the company's near-monopoly on Extreme Ultraviolet (EUV) lithography, a technology essential for manufacturing chips at the five-nanometer level and below.

This emotional reaction has created a disconnect between the stock's discounted forward P/E of 27.8x and its historical valuation.

A deeper analysis of the company's financials reveals a crucial signal: a divergence in its valuation multiples.

While its P/E ratio is at a discount, ASML commands a premium price-to-book (P/B) ratio of 14.6x, which is well above the sector average.

This is a classic indicator that sophisticated investors are recognizing the company's intrinsic value and are willing to pay a premium to own its assets.

The stock's upside, therefore, won't be triggered by new business, but by a shift in sentiment.

For patient investors, buying ASML is not about betting on short-term popularity; it is about owning an indispensable monopoly at a historical discount and waiting for the market to catch up.

👉 Click here to get our closing report to your cell for free!

Tharimmune Inc [THAR] $4.97 (+38.44%)

Tharimmune gained after releasing positive PK simulation data for its TH104 opioid countermeasure, highlighting a 24-hour prophylactic effect against fentanyl exposure.

Immuneering Corp [IMRX] $4.63 (+34.99%)

Immuneering climbed after securing a $25M private placement from top-tier investors at a premium, with data updates from its Phase 2a pancreatic cancer trial expected soon.

Rent The Runway Inc [RENT] $5.61 (+24.39%)

Rent the Runway surged after announcing a growth recapitalization plan that cuts debt, reduces interest costs, and extends maturities with support from APS, STORY3, and Nexus.

Canadian Solar Inc [CSIQ] $10.39 (-18.55%)

Canadian Solar dropped after posting a wider-than-expected Q2 loss of $0.53 per share on weaker revenues, while Trump’s pledge to block new U.S. solar projects and tighten tariffs further hit sector sentiment.

Novavax Inc [NVAX] $7.63 (-12.70%)

Novavax slid after Bank of America downgraded the stock to Underperform, citing limited revenue upside for its COVID and flu vaccine programs despite recent cost-cutting progress.

Hovnanian Enterprises, Inc [HOV] $131.80 (-11.51%)

Hovnanian fell after reporting Q3 EPS of $1.99, missing estimates by more than 40%, as soft U.S. housing demand weighed on results.

Market volatility, policy shifts, and economic tension are leaving many investors overwhelmed.

But buried under the chaos are clear signals of opportunity — if you know where to look.

That’s why we created a free, exclusive guide highlighting 7 stocks positioned for growth as 2025 progresses.

This report includes:

Even in uncertain times, preparation separates winners from watchers.

Download your copy today and get one step closer to smarter, faster trades.

[Claim your free report now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.